Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Operating profit increased on higher revenue and other income. In the pharmaceuticals business, Uptravi, overseas royalty income, Fintepla, Jaypirca and Erleada, among others, showed growth, while sales of protein formulations, sports supplements and other products increased in the functional foods business.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥49,066 million (YoY +24.1%) |
| Operating profit | ¥12,311 million (YoY +22.1%) |
| Ordinary income | ¥12,959 million (YoY +23.4%) |
| Profit attributable to owners of the parent | ¥10,109 million (YoY +22.5%) |
| Net income per share | ¥149.98 |
| Equity ratio | End of the current fiscal period 85.6 / End of previous period 84.2 |
| Total assets | ¥345,153 million |
| Net assets | ¥295,730 million |
| Cash flows from operating activities | ¥1,834 million |
| Cash flows from investing activities | ¥-2,317 million |
| Cash flows from financing activities | ¥-4,373 million |
| Cash and cash equivalents at end of period | ¥72,699 million |
| Full-year earnings forecast | Net Sales ¥200,000 million (YoY +17.1%) / Operating profit ¥38,000 million (YoY +7.1%) / Ordinary income ¥38,600 million (YoY +5.9%) / Net income ¥30,300 million (YoY +1.9%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥124 → ¥124（0.0%） |
| Segment revenue | Pharmaceuticals Business ¥43,256 million (YoY +26.6%), Functional Foods Business ¥5,810 million (YoY +8.0%) |
| Segment profit | Pharmaceuticals Business ¥11,280 million, Functional Foods Business ¥263 million |
| Depreciation and amortization | ¥1,776 million (depreciation and amortization) |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Conference call for institutional investors and securities analysts |
| Issued Shares at Period-End | 70,251,484 Shares |
| Treasury Shares at Period-End | 2,850,555 Shares |
| Factors Behind Changes in Business Performance | Operating profit increased on higher revenue and other income. In the pharmaceuticals business, Uptravi, overseas royalty income, Fintepla, Jaypirca and Erleada, among others, showed growth, while sales of protein formulations, sports supplements and other products increased in the functional foods business. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Operating profit increased due to higher revenue and other income. In the pharmaceuticals business, contributions came from Uptravi, overseas royalty income, Fintepla, Jaypirca and Erleada, among others. In the functional foods business, sales of protein formulations, sports supplements and other products increased.